Navigation Links
Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years

PHILADELPHIA, Pa., Sept. 4 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced new results from a large study that demonstrate combination treatment with AVODART (dutasteride) and the alpha blocker tamsulosin provides significantly greater urinary symptom improvement for men with enlarged prostate than either AVODART or tamsulosin monotherapy over 24 months. Three analyses from the study - Combination therapy with Avodart and tamsulosin (CombAT) - were presented today at the 29th annual meeting of the Societe Internationale d'Urologie in Paris.

In addition, one of three analyses presented -- a post hoc analysis -- showed that AVODART provides a pattern of increasing enlarged prostate symptom improvement over 24 months. Tamsulosin -- the most commonly prescribed medicine for the condition -- provided early symptom improvement, but this improvement plateaued from month three through 24.1 Common symptoms of enlarged prostate include nocturia, frequency and urgency, incomplete emptying, starting and stopping, and weak stream.

The CombAT study includes 4,800 men (combination therapy, n=1492; AVODART, n=1502; tamsulosin, n=1519) with moderate-to-severe enlarged prostate symptoms. All study participants received placebo for four weeks and then were randomized to receive AVODART and tamsulosin combination therapy, AVODART monotherapy, or tamsulosin monotherapy.

Enlarged prostate (also known as benign prostatic hyperplasia (BPH)), is a condition that affects 50 percent of men over the age of 50 and more than 90 percent of men over age 80. AVODART belongs to a class of medicines known as 5 alpha reductase inhibitors (5 ARIs), which shrink the prostate over time. Tamsulosin is an alpha blocker, a class of medicines that relaxes muscles in the bladder and prostate.

"This study provides important new data to guide initial therapy for men with symptomatic BPH," said Claus Roehrborn, M.D., Professor and Chairman, Department of Urology, UT Southwestern Medical Center at Dallas and CombAT principal investigator. "This is the first time we have seen a benefit for combination therapy over monotherapy during the first 12 months of treatment."

CombAT Two-Year Results

The findings reported today are intermediate results from a study that remains active. Researchers will issue a final report at the end of four years regarding the efficacy of AVODART, tamsulosin, and combination therapy in reducing the risk of symptomatic disease progression and the risk of urinary retention (AUR) and prostate surgery in men with moderate-to-severe enlarged prostate symptoms.

Poster presentation: "The effects of dutasteride, tamsulosin, and combination therapy on lower urinary tract symptoms and Qmax in men with BPH and prostatic enlargement"

According to this analysis, the two-year primary endpoint was achieved in the CombAT study. Symptom improvement was measured using the International Prostate Symptom Score (IPSS), a validated assessment questionnaire recommended by the American Urological Association (AUA). Over 24 months, AVODART and tamsulosin combination therapy provided a significantly greater (p < 0.001) improvement in symptoms (IPSS) from baseline (6.2 units) than either AVODART (4.9 units) or tamsulosin (4.3 units) treatment alone. In fact, the CombAT study demonstrated the benefit of combination therapy over both monotherapies in the first 12 months of treatment. With combination therapy, patients experienced continuous improvement of symptoms throughout the two years of the study.

Poster presentation: "Dutasteride provides greater improvement in symptoms and Qmax than tamsulosin in men with moderate-to-severe symptoms of BPH and prostate enlargement"

This post hoc analysis of the CombAT two-year data is a comparison of efficacy for AVODART and tamsulosin monotherapies. According to the post hoc analysis, AVODART monotherapy resulted in a pattern of continuous and increasing symptom improvement over 2 years (IPSS at Month 3: 2.8 units; IPSS at Month 24: 4.9 units). Patients taking tamsulosin showed similar symptom improvement at Month 3 through Month 24 (IPSS at Month 3: 4.5 units; IPSS at Month 24: 4.3 units). Furthermore, AVODART resulted in continuous and sustained Qmax (urine flow rate) improvements to Month 24.

The third analysis presented covered the safety and tolerability of the treatment regimens. All therapy regimens employed in the study appear to be generally well-tolerated. The profile of events for combination therapy was consistent with those reported for monotherapies. The most common adverse events for combination therapy were erectile dysfunction (7.4%), retrograde ejaculation (4.2%) and altered or decreased libido (3.4%). The most common adverse events for AVODART monotherapy were erectile dysfunction (6.0%), altered or decreased libido (2.8%) and breast enlargement (1.8%), while the most common adverse events for tamsulosin monotherapy were erectile dysfunction (3.8%), altered or decreased libido (1.7%) and dizziness (1.7%).

About CombAT

CombAT is a multicenter, randomized, double-blind and parallel-group study. Men [aged greater than or equal to 50 years with a prostate volume (PV) greater than or equal to 30 cc, serum prostate-specific antigen (PSA) level 1.5-10 ng/mL, Qmax > 5 and less than or equal to 15 mL/sec with a minimum voided volume greater than or equal to 125 mL and International Prostate Symptom Score (IPSS) greater than or equal to 12] with moderate-to-severe enlarged prostate symptoms received placebo for four weeks and were then randomized to receive AVODART 0.5 mg/day and tamsulosin 0.4 mg/day (n=1492), AVODART 0.5 mg/day (n=1502), or tamsulosin 0.4 mg/day (n=1519).


AVODART, the first and only dual 5ARI for the treatment of enlarged prostate, inhibits both the type I and type II isoenzymes responsible for the conversion of testosterone into dihydrotestosterone (DHT). DHT is the primary male hormone responsible for the enlargement of the prostate. AVODART provides the power to suppress DHT by 93 percent at 2 years. Over time, AVODART reduces prostate volume, improves symptoms and arrests the enlarged prostate disease process.

AVODART is indicated for the treatment of symptomatic enlarged prostate in men with an enlarged prostate to improve urinary symptoms, reduce the risk of AUR, and reduce the risk of enlarged prostate-related surgery. While some men have fewer problems and symptoms after three months of treatment with AVODART, a treatment period of at least six months is usually necessary to see if AVODART will improve symptoms.

Only a doctor can tell if symptoms are from an enlarged prostate and not a more serious condition such as prostate cancer. Men should see their doctors for regular exams. Women and children should not take AVODART. Women who are, or could become pregnant should not handle AVODART due to the potential risk of a specific birth defect. Men treated with AVODART should not donate blood until at least six months after their final dose.

Caution should be used in patients with liver disease. Possible side effects include sexual side effects and breast tenderness and/or swelling. These side effects occur infrequently.

For full prescribing information, see

About Enlarged Prostate

Enlarged prostate is a prevalent and progressive condition that affects 50 percent of men over 50 years of age and over 90 percent of men older than age 80. An enlarged prostate causes changes in urinary habits because of its location around the urethra. Over time, the prostate can continue to grow and urinary symptoms may worsen as the bladder loses the ability to empty itself. Left untreated, in severe cases, an enlarged prostate can lead to serious long-term problems including acute urinary retention (AUR) and the need for surgery, and in rare cases even kidney or bladder damage.

About GlaxoSmithKline

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Company information line: 1-888-825-5249. Website address:

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this press release, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the 'Operating and Financial Review and Prospects' in the company's Annual Report 2006.

Contact: Robert Perry


(919) 483 2839

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:10/8/2015)... Oct. 8, 2015  Allergan plc (NYSE: AGN ... it will hold its R&D Day on November 4, ... – to 1:00 p.m. PT). The company will also ... at 9:00 a.m. ET (6:00 a.m. PT). ... --> Logo - ...
(Date:10/8/2015)... CAMBRIDGE, Mass. , Oct. 8, 2015 /PRNewswire/ ... has awarded approximately $40 million to the Broad ... whole genome sequencing of 20,000 individuals, as well ... sequencing and metabolite profiling. Trans-Omics for ... an initial step toward a larger initiative, which ...
(Date:10/8/2015)... FRANCISCO , Oct. 8, 2015  Nektar Therapeutics ... the Company,s pain and oncology portfolio during an Investor ... - 3:30 p.m. Eastern Time in New ... carcinoma.  Details of the NKTR-214 Phase 1/2 clinical program ... CD122-biased immune-stimulatory cytokine designed to preferentially stimulate the production ...
Breaking Medicine Technology:
... (SIX: RO, ROG; OTCQX: RHHBY) announced today that the David ... be using the Roche LightCycler ® 480 System, a ... gene expression and genetic variation, in advanced cancer research. ... 480 System to support several key areas of research it ...
... 2011 /PRNewswire/ -- Royal Philips Electronics ... States availability of the Ingenia MRI system, the ... Previously available in Europe, Canada and Japan, the ... Food and Drug Administration. Driven by Philips commitment ...
Cached Medicine Technology:
(Date:10/10/2015)... ... October 10, 2015 , ... The Bank of America 500 NASCAR Sprint Cup ... Saturday, October 10th, defending race winner, Kevin Harvick, will battle it out for the ... and all of the stars of the NASCAR Sprint Cup Series. As part ...
(Date:10/10/2015)... ... October 10, 2015 , ... In the inaugural people’s choice contest, entitled Bold ... Work in Jacksonville, amongst medium-sized companies with 25 – 99 employees. The announcement was ... a celebratory gala on October 1st. , Many of the features of the ...
(Date:10/9/2015)... ... October 09, 2015 , ... With the FCPX LUT Vibrance pack ... footage. A LUT is a Lookup Table that contains a mathematical formula for modifying ... the table. This pack comes with 60 vibrant CUBE LUT files. , ...
(Date:10/9/2015)... CA (PRWEB) , ... October 09, 2015 , ... ... now offering a special promotion on Invisalign, the orthodontic system that uses clear, ... The aligners are almost invisible against the teeth, which allow patients to complete ...
(Date:10/9/2015)... ... 09, 2015 , ... Confidence Plus Insurance has just celebrated ... initiative that involves working with a series of local charities throughout the California ... Insurance is the Gleason Park Electric Violin Ensemble (GPEVE). , GPEVE provides a ...
Breaking Medicine News(10 mins):
... , New Report Highlights Best and Worst State ... Va., Sept. 10 A new report by The Vision Council, ... for children entering school are inconsistent, impeding children,s ability to succeed ... visual processing of information, undetected vision problems can severely impact a ...
... largest network of Hispanic health advocates joins President Obama,s efforts to improve ... , WASHINGTON, Sept. 9 "There was a clear ... reform. We need to work together to get the job done and ... our history, it is essential that we do this to support America,s ...
... , Statement attributable to: J. James Rohack, M.D. President, ... that Medical Liability Reform is Needed , , ... is unacceptable. The AMA will continue to work for reform that makes ... opportunity this year to achieve meaningful health reform for America,s patients and ...
... Sept. 9 In commemoration of the first September 11 National ... Los Angeles will host three 2-hour volunteer orientations for 100+ youth and ... tour of the chapter,s new state of the art Emergency Operation Center, ... recent California wildfires. , , What: ...
... MECHANICSBURG, Pa., Sept. 9 Select Medical Holdings ... the launch of its initial public offering of 33,333,333 shares ... is expected to be between $11.00 and $13.00 ... of common shares by Select, and Goldman, Sachs & Co., ...
... 9 As the nation awaits President Obama,s address on ... Philanthropic Collaborative (TPC) sent today a letter to the President ... foundations in the field of health. , , ... the social and economic effectiveness of health-related philanthropic activities. ...
Cached Medicine News:
CDIs new improved Implant Stabilizer has super-soft elastic bands with lace trim....
Bras and Breast Support...
Post-Surgical compression garments...
... The Albumin Cobalt Binding (ACB®) Test is ... Modified Albumin (IMA®) by measuring the cobalt ... serum sample. First identified in the early ... comes in contact with ischemic tissue in ...
Medicine Products: